Nifurtimox and Eflornithine for Sleeping Sickness
Author Information
Author(s): Francesco Checchi, Patrice Piola, Harriet Ayikoru, Florence Thomas, Dominique Legros, Gerardo Priotto
Primary Institution: Epicentre, Paris, France
Hypothesis
Can the combination of nifurtimox and eflornithine effectively treat late-stage sleeping sickness?
Conclusion
The combination of nifurtimox and eflornithine shows promising efficacy and safety for treating late-stage sleeping sickness.
Supporting Evidence
- All 31 patients were discharged alive.
- No treatment-related deaths were reported.
- Efficacy ranged from 90.3% to 100.0% based on different analysis methods.
- Neutropenia was a common adverse event, affecting 9 out of 31 patients.
Takeaway
Doctors tested a new medicine mix to help sick people in Africa, and it worked really well without causing many problems.
Methodology
Patients received a combination of nifurtimox and eflornithine, and their health was monitored for 24 months.
Potential Biases
Possible ascertainment bias regarding mild adverse events.
Limitations
The study lacked a comparator group and had a small sample size.
Participant Demographics
{"female_percentage":48.4,"mean_age":23.9,"mean_weight":44.8,"mean_body_mass_index":18.2}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website